With the increasing use of cardiac electronic implantable devices in recent years, the identification of asymptomatic atrial arrhythmias, including atrial high-rate episodes (AHREs) and device-detected subclinical atrial fibrillation (SCAF), has become common in clinical practice. AHREs have potentially important clinical implications because they are considered precursors of atrial fibrillation (AF). Although to a lesser extent than clinical AF, both AHREs and device-detected SCAF are associated with thromboembolic events, however routine use of anticoagulants in these conditions is not recommended. In addition, patients with AHREs are at increased risk of cardiovascular events, including myocardial infarction, heart failure, and cardiovascular hospitalization. The relationship between stroke and AHREs and the potential benefit of anticoagulant therapy in this setting is the subject of ongoing debate. In this review, we aimed to appraise the available evidence and current gaps in the risk stratification and management of patients with AHREs/device-detected SCAF.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2024.132921DOI Listing

Publication Analysis

Top Keywords

atrial high-rate
8
high-rate episodes
8
episodes ahres
8
ahres device-detected
8
atrial fibrillation
8
ahres
6
atrial
5
antithrombotic therapy
4
therapy patients
4
patients atrial
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!